Lantheus Holdings Inc (LNTH) - News Archive

In a significant development for Lantheus Holdings, Inc. (NASDAQ: LNTH), the Portnoy Law Firm has announced a class-action lawsuit on behalf of investors who purchased the company s securities between February 26, 2025,...

In a recent notice from The Gross Law Firm, shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH) were reminded of an urgent deadline to join a class-action lawsuit against the company, set for November 10, 2025. As in...

In an unfolding situation that has caught the attention of the investment community, Lantheus Holdings, Inc. (NASDAQ: LNTH) finds itself under the investigative lens of the Pomerantz Law Firm. The firm is probing claims...

In a significant stride for the field of nuclear medicine, Lantheus Holdings, Inc., a leading radiopharmaceutical company, has announced the presentation of promising new data at the upcoming 2025 Society of Nuclear Med...

BEDFORD, Mass. April 1, 2025 — In a significant move projected to reshape the landscape of radiopharmaceuticals, Lantheus Holdings, Inc. (NASDAQ: LNTH), has finalized its acquisition of Evergreen Theragnostics, Inc. a c...

In a significant advance for the field of radiopharmaceuticals, Lantheus Holdings, a leader in medical imaging and diagnostics, has announced its intent to acquire Evergreen Theragnostics in a move designed to bolster i...

Lantheus Holdings Strengthens Market Position with Strategic Developments in Alzheimer’s DiagnosticsIn the fast-evolving landscape of medical diagnostics, Lantheus Holdings Inc. (NASDAQ: LNTH) is making significant stri...

Lantheus Holdings Strategic Share Repurchase: A $250 Million Commitment to Growth and Shareholder ValueIn a strategic move aimed at enhancing shareholder value and reflecting confidence in its business model, Lantheus H...

Lantheus Applauds CMS 2025 Payment Rule Enhancements for Diagnostic Radiopharmaceuticals: PYLARIFY Positioned for Continued SuccessLantheus Holdings, Inc. a key player in the radiopharmaceutical industry, has recently e...

In a significant move for the healthcare landscape, Lantheus Holdings, Inc. has expressed its commendation for the Centers for Medicare & Medicaid Services (CMS) recent rule concerning the calendar year 2025 Medicare Ho...

In a pivotal moment for prostate cancer therapy, Lantheus Holdings, Inc. has presented compelling findings from the Phase 3 SPLASH trial at the 2024 European Society for Medical Oncology (ESMO) Congress. This landmark t...

Lantheus Acquires NAV-4694, Enhancing Alzheimer s Diagnostic ToolboxLantheus, a leading provider of diagnostic medical imaging agents, announced its acquisition of NAV-4694, a next-generation amyloid PET imaging agent d...

Lantheus Holdings Inc Shares Trail Performance of Entire Market: An Analysis of Recent EventsIn this week, Lantheus Holdings Inc shares have been trailing the overall performance of the market. This could be attributed...

Harnessing Precision Medicine: Lantheus Expands Therapeutic and Diagnostic Horizons in Prostate and Breast Cancer The fight against cancer continues to evolve with remarkable innovations, bringing new hope for improved...

Harnessing AI to Transform Diagnostic Imaging: A New Frontier in Prostate Cancer Detection By At the confluence of artificial intelligence and medical imaging, a significant breakthrough is making waves in the realm of...

Lantheus Announces FDA Approval of DEFINITY (Perflutren Lipid Microsphere) for Pediatric Patients; Solidifies its Position as the Leading Ultrasound Enhancing Agent for Suboptimal Echocardiograms in the U.S.In a recent...

Alzheimer s Disease (AD) is a devastating neurodegenerative disorder characterized by the presence of abnormal tau protein tangles in the brain. In a remarkable development for AD research, Lantheus Holdings Inc has ann...

As the medical technology industry experiences significant changes in cancer treatments, enterprises have started to acknowledge the potential of strategic collaborations to boost radiopharmaceutical oncology pipelines....